Exclusion by age, cardiovascular comorbidity and malignancies are the main factors that impact generalizability of evidence from trials to the real-world situation in older adults with psoriasis
J Eur Acad Dermatol Venereol
.
2023 Dec;37(12):e1471-e1474.
doi: 10.1111/jdv.19368.
Epub 2023 Aug 2.
Authors
E L M Ter Haar
1
,
J M P A van den Reek
1
,
E E Ten Bruin
1
,
E M Bronkhorst
2
,
R J Borgonjen
3
,
M M Kleinpenning
4
,
E N Kop
5
,
M B Visch
6
,
P C M van de Kerkhof
1
,
E M G J de Jong
1
,
S F K Lubeek
1
Affiliations
1
Department of Dermatology, Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands.
2
Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands.
3
Department of Dermatology, Gelderse Vallei Hospital and Padberg Clinic, Ede, The Netherlands.
4
Department of Dermatology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
5
Department of Dermatology, Bernhoven Hospital, Uden, The Netherlands.
6
Department of Dermatology, Rijnstate Hospital, Arnhem, The Netherlands.
PMID:
37471529
DOI:
10.1111/jdv.19368
No abstract available
Publication types
Letter
MeSH terms
Aged
Cardiovascular Diseases* / complications
Cardiovascular Diseases* / epidemiology
Comorbidity
Humans
Lung
Neoplasms* / complications
Neoplasms* / epidemiology
Psoriasis* / complications
Psoriasis* / epidemiology
Grants and funding
n/a/Almirall